SHR-4602
- Generic Name
- SHR-4602
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06704828
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
Phase 1
Withdrawn
- Conditions
- HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06560138
- Locations
- 🇦🇺
Scientia Clinical Research Limited, Randwick, New South Wales, Australia
🇦🇺Macquarie University, Sydney, New South Wales, Australia
🇦🇺Icon Cancer Centre South Brisbane, Brisbane, Queensland, Australia
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06516926
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath